Bupropion-Associated Skin Rash
Bupropion should be discontinued if a skin rash is accompanied by features of hypersensitivity (e.g., pruritus, hives, chest pain, edema, or shortness of breath). [1] Severe cutaneous adverse reactions require immediate emergency evaluation. [1][2]
Immediate Actions When a Rash Appears
Bupropion should be stopped and urgent medical evaluation obtained when an allergic or anaphylactoid/anaphylactic reaction is suspected. [1] Emergency care should be sought when a rash is associated with blistering or skin peeling, mucosal involvement (mouth/eyes/genitals), or systemic symptoms such as fever. [1][2]
Hypersensitivity and Anaphylaxis Features
Hypersensitivity reactions reported with bupropion include skin rash with pruritus, hives, chest pain, edema, and shortness of breath. [1] If these manifestations are present during treatment, discontinuation of bupropion and urgent evaluation are recommended. [1]
Severe Cutaneous Adverse Reaction Red Flags
Stevens-Johnson syndrome is suggested by blistering and involvement of mucous membranes. [2] Urgent emergency assessment is recommended for suspected Stevens-Johnson syndrome due to the risk of rapid progression and serious complications. [2]
Medication Rechallenge Avoidance
Restarting bupropion after suspected hypersensitivity or severe cutaneous adverse reaction should be avoided pending specialist assessment. [1][8]
Supportive Care Until Evaluation
Symptomatic skin-directed measures may be used for comfort while awaiting medical evaluation. [6] Avoidance of further bupropion dosing until medical assessment is completed is recommended. [1]
Clinical Follow-Up After Rash Resolution
Evaluation should determine whether the rash represents a mild, non-allergic drug eruption versus a hypersensitivity reaction or severe cutaneous adverse reaction. [1][6] Bupropion should be permanently discontinued if a hypersensitivity reaction is confirmed. [1]
Safety Considerations for Decision-Making
Bupropion has warnings for hypersensitivity and severe skin reactions in prescribing information. [1][7] Rash associated with systemic symptoms or mucosal lesions should be treated as a medical emergency. [1][2][8]
Key Documentation to Provide Clinicians
The onset timing relative to the first bupropion dose should be provided. [1] Presence of hives, itching, swelling (face or throat), breathing symptoms, blistering, skin peeling, eye redness, or sores in the mouth or other mucosal areas should be documented. [1][2][8]